BC
ELEV

BIT Capital’s Elevation Oncology ELEV Stock Holding History

BIT Capital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,456
Closed -$56K – 145
2023
Q1 		$56K Buy
+29,456
New +$38K 0.01% 133

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BIT Capital's ELEV Position: Q2 2023 in Review

BIT Capital sold out of Elevation Oncology (ELEV) in Q2 2023, closing a stake of 29,456 shares — an estimated $56K sold.

BIT Capital first reported a position in ELEV in Q1 2023 and held it in 1 quarter. The position peaked at $56K in Q1 2023. 39 funds tracked by Wall St. Rank hold ELEV as of Q2 2023.

  • BIT Capital reported no remaining Elevation Oncology position as of Q2 2023 after selling out during the quarter.
  • BIT Capital sold 29,456 Elevation Oncology shares in Q2 2023, an estimated $56K.
  • BIT Capital first reported a position in Elevation Oncology in Q1 2023 and held it in 1 quarter.
  • BIT Capital's Elevation Oncology position peaked at $56K in Q1 2023.
  • 39 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2023.

Based on BIT Capital's 13F filing for Q2 2023, filed 12 Feb 2025.